Physician profile
Phillip Wayne Johnson
NPI 1225089683
$5,172.46
in general payments reported to CMS, 2019-2025
45 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $125 · 2021: $208 · 2022: $601 · 2023: $1,514 · 2024: $1,162 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,878 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,877.70 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $694.97 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $673.27 | 2021-2025 | |
| Pfizer INC. | $511.51 | 2019-2025 | |
| Novo Nordisk INC | $337.32 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $225.74 | 2022-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Novartis Pharmaceuticals Corporation | $217.24 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $189.58 | 2022-2025 | Ingrezza |
| Abbott Laboratories | $169.96 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.32 | 2019-2025 | Ofev, Jardiance, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $153.01 | 2024 | Cobenfy |
| Amgen INC. | $149.52 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $145.66 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Lundbeck LLC | $140.01 | 2023-2025 | Rexulti |
| Corcept Therapeutics | $135.29 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $120.86 | 2019-2025 | Breztri, Farxiga |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.